No, you do not need to add Lovenox to Eliquis after hip fracture repair
If the patient was already on Eliquis (apixaban) prior to surgery for another indication (such as atrial fibrillation or prior VTE), you should resume the therapeutic dose of Eliquis postoperatively once hemostasis is achieved—typically 24-72 hours after surgery—without adding Lovenox. However, if VTE prophylaxis is needed in the immediate postoperative period before resuming therapeutic Eliquis, you may use prophylactic-dose Lovenox temporarily, stopping it 12 hours before restarting therapeutic Eliquis to avoid overlap 1.
Clinical Context and Decision Algorithm
If Patient Was on Eliquis Pre-operatively:
The French Working Group on Perioperative Hemostasis (GIHP) 2017 guidelines provide clear direction 1:
Preoperatively: Eliquis should be held for 2-3 days before hip fracture surgery (depending on renal function and bleeding risk)
Postoperatively:
- If VTE prophylaxis is indicated in the immediate postoperative period (first 6-72 hours), use prophylactic-dose heparin (UFH or LMWH like Lovenox) starting at least 6 hours after surgery
- Resume therapeutic-dose Eliquis 24-72 hours postoperatively once surgical hemostasis is confirmed
- Critical timing: Give the first therapeutic Eliquis dose 12 hours after the last prophylactic Lovenox dose to avoid dangerous overlap 1
If Patient Was NOT on Anticoagulation Pre-operatively:
Hip fracture surgery itself requires VTE prophylaxis. The 2022 AAOS Hip Fracture Guidelines strongly recommend VTE prophylaxis for all hip fracture patients 2. You have several options:
Option 1: Eliquis alone (FDA-approved for this indication 3)
- 2.5 mg twice daily starting 12-24 hours post-surgery
- Continue for 5 weeks after total hip replacement or 2 weeks after hip fracture repair 1
- Superior efficacy to enoxaparin with similar or lower bleeding rates 4, 5
Option 2: Lovenox alone (FDA-approved 6)
- 30 mg subcutaneously every 12 hours OR 40 mg once daily
- Start 12-24 hours post-surgery after hemostasis established
- Continue for 10-14 days minimum, up to 4 weeks 7, 2, 6
Option 3: Sequential therapy (if patient will transition to long-term Eliquis)
- Start prophylactic Lovenox 6-12 hours post-surgery
- Transition to Eliquis 2.5 mg twice daily after 24-72 hours
- Stop Lovenox 12 hours before first Eliquis dose 1
Key Evidence Supporting Single-Agent Approach
The ADVANCE-3 trial demonstrated apixaban's superiority over enoxaparin for hip replacement surgery, with a relative risk of 0.36 (95% CI 0.22-0.54, P<0.001) for VTE and lower bleeding rates 8, 4. A 2022 national database study of 11,384 hip fracture patients found Eliquis and Lovenox had comparable 90-day VTE rates (3.8% vs 3.1%, not statistically different after adjustment), while Eliquis had significantly lower transfusion rates 9.
Critical Pitfalls to Avoid
Never overlap therapeutic doses: Combining therapeutic Eliquis with any dose of Lovenox dramatically increases bleeding risk without additional VTE protection 1
Timing matters: If using sequential therapy, maintain the 12-hour gap between last Lovenox dose and first therapeutic Eliquis dose 1
Check renal function: Both drugs require dose adjustment or avoidance in severe renal impairment (CrCl <30 mL/min for Eliquis, <30 mL/min for Lovenox) 1
Epidural catheter considerations: If an epidural catheter is present, therapeutic anticoagulation must be managed with heparin (not DOACs) to allow safe catheter removal 1
Warfarin is inferior: If considering alternatives, avoid warfarin—it had significantly higher VTE rates (5.0%) compared to both Eliquis and Lovenox in hip fracture patients 9
Practical Recommendation
For a patient already on Eliquis: Resume therapeutic Eliquis alone 24-72 hours post-surgery. Consider prophylactic Lovenox only in the immediate 6-24 hour postoperative window if needed, stopping it 12 hours before restarting Eliquis.
For a patient not previously anticoagulated: Choose either Eliquis 2.5 mg twice daily OR Lovenox 30 mg every 12 hours as monotherapy—do not combine them. Eliquis offers the advantage of oral administration and potentially lower bleeding risk 9, 10, 4.